Mental Health Daily

Black Americans Diagnosed with Schizophrenia 2.42x the Rate of White Americans: More Negative Symptoms

by GLOOM

Photoreal illustration representing racial stress and mental health, with conceptual imagery of contemplation, identity, and cognitive pathways.

Black Americans are diagnosed with schizophrenia-spectrum disorders at 2.42 times the rate of White Americans, and they also score higher on negative-symptom measures than White patients carrying the same diagnosis.2 A 2026 paper by Spann and colleagues asks why. Research Highlights Black Americans are diagnosed with schizophrenia-spectrum disorders at 2.42x the rate of White Americans, …

Risperidone Stroke Risk in Dementia: HR 1.28 Across CVD Subgroups

by GLOOM

Conceptual illustration of cerebral blood vessels and a pill, representing risperidone-associated stroke risk in dementia patients.

The risperidone-stroke link in dementia is one of the longest-running safety signals in geriatric psychiatry, anchoring the FDA’s 2005 black-box warning on atypical antipsychotic mortality. Popular framing reduces it to “antipsychotics cause stroke in dementia” — a true sentence that flattens a multi-axis decision. Choma’s 2025 analysis of UK primary care records is the largest …

SSRIs + DOACs: No Excess Bleeding vs. Other Antidepressants

by GLOOM

Stylized illustration of an SSRI capsule alongside a DOAC tablet against a vascular network background, representing the bleeding-interaction question in primary care.

SSRIs raise bleeding risk on their own. DOACs (direct oral anticoagulants — apixaban, rivaroxaban, dabigatran, edoxaban) raise it more. The intuitive worry is that combining them stacks the two effects. A new BJGP Open analysis from Chau and colleagues argues the stacking is smaller than most popular framings claim, and that the real safety question …

Lithium in Pregnancy: Why Late Discontinuation Backfires

by GLOOM

Photoreal illustration representing lithium prescribing decisions during pregnancy, with imagery of a pregnant figure and pharmaceutical motifs.

Lithium prescribing during pregnancy sits in a knot of competing risks. The teratogenicity data have been recalibrated dramatically since the 1970s, while the postpartum-relapse data have moved in the opposite direction. Most popular framing still treats lithium as a uniquely dangerous fetal exposure to be avoided when possible. The new Chauhan UK cohort shows what …

Maternal Health and Autism Risk: Most Links Are Genetic, Not Prenatal

by GLOOM

Stylized illustration of a multi-generation family tree branching into cousin pairs, representing the 3-generation registry design used to separate inherited from in-utero genetic effects on autism risk.

For two decades, headlines have linked autism to maternal obesity, depression, anxiety, gestational diabetes, infection, autoimmune disease, and antidepressant use. The studies behind those headlines are well-replicated registry associations. A new design from the Aarhus University iPSYCH group offers the most careful answer yet to what they mean for an individual pregnancy. Most “maternal X …

Ketamine Addiction After One Therapeutic Dose: How Rare Is It?

by GLOOM

Stylized illustration evoking the tension between ketamine's clinical promise for depression and its abuse liability, framed in muted rose and amber tones for the addiction topic.

Ketamine and its S-enantiomer esketamine (sold as Spravato) are now established treatments for treatment-resistant depression and acute suicidality. The standard safety pitch from sponsors and clinics: at single sub-anesthetic doses, in supervised settings, addiction risk is minimal. A new case report in BJPsych Open documents a patient for whom that pitch failed catastrophically — and …

Schizophrenia and Aging: Advanced, Not Accelerated

by GLOOM

Two parallel timelines representing chronological vs. biological age in schizophrenia: an early offset at first episode, then parallel trajectories afterward — illustrating advanced rather than accelerated aging.

“Schizophrenia ages you faster” is the headline that gets repeated whenever a new biomarker study lands. The 2026 Fernandez-Egea, Garcia-Rizo and Kirkpatrick review — covering 170 studies across mortality, brain imaging, telomeres, epigenetic clocks, and metabolic markers — pushes back on that framing.2 The aging signal is genuine. “Accelerated” is the part that overshoots for …